RxDoctor Payments Data

John Pacella, MD

Cardiovascular Disease · Pittsburgh, PANPI 1972530517

Payments from drug & device makers

$27,607in general payments, 2019–2025

Across 143 payments — averaging $193.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lantheus Medical Imaging, Inc.$14K
  • Recor Medical Inc$11K
  • Amgen$360
  • Johnson & Johnson$354
  • Boehringer Ingelheim$317
  • Abbott$238
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,88596%
  • Education$1124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,607 in reported general payments places this provider in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$104,385
Medicare patients
2,111
Services billed
3,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban114$136,021
Repatha SureclickEvolocumab83$75,473
JardianceEmpagliflozin45$46,449
EntrestoSacubitril/Valsartan39$40,525
XareltoRivaroxaban33$38,734
VascepaIcosapent Ethyl21$6,824
FarxigaDapagliflozin Propanediol11$6,637
Atorvastatin Calcium298$3,724
Ezetimibe116$2,591
Rosuvastatin Calcium162$2,115
Metoprolol Succinate129$1,800
Isosorbide Mononitrate ErIsosorbide Mononitrate91$1,384
Metoprolol Tartrate172$1,188
Ranolazine ErRanolazine17$1,001
Nitroglycerin27$891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$136$136,021114 claims
Boehringer IngelheimJardiance$317$46,44945 claims
NovartisEntresto$194$40,52539 claims
Johnson & JohnsonXarelto$354$38,73433 claims
AstraZenecaFarxiga$66$6,63711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →